444 related articles for article (PubMed ID: 32562659)
41. Profile of ospemifene in the breast.
Berga SL
Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
[TBL] [Abstract][Full Text] [Related]
42. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
Simon J; Portman D; Mabey RG;
Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
[TBL] [Abstract][Full Text] [Related]
43. CO
Salvatore S; Pitsouni E; Grigoriadis T; Zacharakis D; Pantaleo G; Candiani M; Athanasiou S
Climacteric; 2021 Apr; 24(2):187-193. PubMed ID: 33089713
[TBL] [Abstract][Full Text] [Related]
44. Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Sussman TA; Kruse ML; Thacker HL; Abraham J
J Oncol Pract; 2019 Jul; 15(7):363-370. PubMed ID: 31291563
[TBL] [Abstract][Full Text] [Related]
45. New therapeutic option in genitourinary syndrome of menopause: pilot study using microablative fractional radiofrequency.
Kamilos MF; Borrelli CL
Einstein (Sao Paulo); 2017; 15(4):445-451. PubMed ID: 29364367
[TBL] [Abstract][Full Text] [Related]
46. Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors.
Zuo SW; Wu H; Shen W
Menopause; 2018 Jul; 25(7):828-836. PubMed ID: 29533365
[TBL] [Abstract][Full Text] [Related]
47. Genitourinary syndrome of menopause and the use of laser therapy.
Hutchinson-Colas J; Segal S
Maturitas; 2015 Dec; 82(4):342-5. PubMed ID: 26323234
[TBL] [Abstract][Full Text] [Related]
48. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Portman DJ; Bachmann GA; Simon JA;
Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
[TBL] [Abstract][Full Text] [Related]
49. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy.
Bruyniks N; Biglia N; Palacios S; Mueck AO
Climacteric; 2017 Jun; 20(3):195-204. PubMed ID: 28267367
[TBL] [Abstract][Full Text] [Related]
50. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
51. No. 358-Intravaginal Laser for Genitourinary Syndrome of Menopause and Stress Urinary Incontinence.
Walter JE; Larochelle A
J Obstet Gynaecol Can; 2018 Apr; 40(4):503-511. PubMed ID: 29680080
[TBL] [Abstract][Full Text] [Related]
52. Vulvar and vaginal fractional CO2 laser treatments for genitourinary syndrome of menopause.
Streicher LF
Menopause; 2018 May; 25(5):571-573. PubMed ID: 29406425
[TBL] [Abstract][Full Text] [Related]
53. Update on management of genitourinary syndrome of menopause: A practical guide.
Palacios S; Castelo-Branco C; Currie H; Mijatovic V; Nappi RE; Simon J; Rees M
Maturitas; 2015 Nov; 82(3):308-13. PubMed ID: 26261035
[TBL] [Abstract][Full Text] [Related]
54. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.
Eder SE
Womens Health (Lond); 2014 Sep; 10(5):499-503. PubMed ID: 25335541
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness of CO
Angioli R; Stefano S; Filippini M; Pieralli A; Montera R; Plotti F; Gatti A; Bartolone M; Luvero D
Int J Gynecol Cancer; 2020 May; 30(5):590-595. PubMed ID: 32221022
[TBL] [Abstract][Full Text] [Related]
56. Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy.
Quick AM; Zvinovski F; Hudson C; Hundley A; Evans C; Stephens JA; Arthur E; Ramaswamy B; Reinbolt RE; Noonan AM; VanDeusen JB; Wesolowski R; Stover DG; Williams NO; Sardesai SD; Faubion SS; Loprinzi CL; Lustberg MB
Menopause; 2021 Feb; 28(6):642-649. PubMed ID: 33534429
[TBL] [Abstract][Full Text] [Related]
57. Vaginal CO2 laser therapy versus sham for genitourinary syndrome of menopause management: a systematic review and meta-analysis of randomized controlled trials.
Khamis Y; Abdelhakim AM; Labib K; Islam BA; Nassar SA; Motaal AOA; Saleh DM; Abdou H; Abbas AM; Mojahed EM
Menopause; 2021 Aug; 28(11):1316-1322. PubMed ID: 34374686
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study.
Filippini M; Luvero D; Salvatore S; Pieralli A; Montera R; Plotti F; Candiani M; Angioli R
Menopause; 2020 Jan; 27(1):43-49. PubMed ID: 31794500
[TBL] [Abstract][Full Text] [Related]
59. Sexual Function Post-Breast Cancer.
Streicher L; Simon JA
Cancer Treat Res; 2018; 173():167-189. PubMed ID: 29349764
[TBL] [Abstract][Full Text] [Related]
60. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.
Kangas L; Unkila M
Steroids; 2013 Dec; 78(12-13):1273-80. PubMed ID: 24055829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
